Project description
Accelerating pandemic preparedness: antivirals for known and newly identified threats
Antiviral medications help the body fight viral infections. They minimise the symptoms, shorten their duration and potentially reduce the risk of spreading the virus. Increasing pandemic preparedness will include developing broad spectrum antiviral therapeutics for infectious diseases with epidemic – and subsequently pandemic – potential. The EU-funded AVITHRAPID project plans to establish an early-stage drug discovery pipeline targeting several viruses and building on a pre-existing set of promising bioactive small molecules. The project will leverage cutting-edge preclinical drug discovery techniques and test an existing candidate small molecule in clinical trials. Furthermore, the team plans to identify additional viral targets to accelerate research on their corresponding antiviral targets.
Objective
"The European Consortium ""Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases"" (AVITHRAPID) aims to support the search for novel broad-spectrum antiviral compounds by advancing multiple approaches.
Building on a pre-existing set of bioactive small molecules, which are at least at the validated hit level, AVITHRAPID strives for the development of pre-clinical candidates targeting several viruses. This will be achieved by combining the relevant expertise
for pre-clinical drug discovery, including molecular modeling, biochemical and cell-based assays, X-ray crystallography, medicinal chemistry, biophysical binding studies, ADMETox profiling, in vitro and in vivo PK, as well as animal disease models. In addition, the consortium aims to conduct a Phase 2a clinical trial for a small molecule developed against Zika virus.
Moreover, the consortium aims to identify and validate further viral targets and thereby contribute to the search for novel antiviral targets. As a consequence of the activities in AVITHRAPID, an early-stage drug discovery pipeline will be established that can be used to rapidly identify and develop novel antiviral compounds against emerging diseases."
Fields of science
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health sciencesbasic medicinemedicinal chemistry
- natural sciencesearth and related environmental sciencesgeologymineralogycrystallography
- medical and health scienceshealth sciencesinfectious diseases
Programme(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
80686 Munchen
Germany
See on map
Participants (16)
01100 Viterbo
See on map
00152 Roma Rm
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
34149 Basovizza Trieste
See on map
80138 Napoli
See on map
1098XH Amsterdam
See on map
00149 Roma
See on map
53100 Siena
See on map
1649 028 Lisboa
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
09124 Cagliari
See on map
37020 Tours
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
75654 Paris
See on map
LV-1006 Riga
See on map
00133 Roma
See on map
708 00 Ostrava Poruba
See on map
20122 Milano
See on map
75007 Paris
See on map
Partners (2)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
4123 Allschwil
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
6900 Lugano
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.